MicroRNA 629 (miR-629)

MicroRNA 629 (miR-629) is a small, non-coding RNA belonging to the microRNA family, typically about 19–25 nucleotides long, that regulates gene expression at the post-transcriptional level by binding to complementary sequences in the 3′ untranslated regions (3′-UTR) of target mRNAs, leading to mRNA degradation or translational repression[1]. miR-629 is frequently upregulated in several human cancers—including pancreatic cancer, non-small cell lung cancer, prostate cancer, breast cancer, and renal cell carcinoma—where it promotes cell proliferation, invasion, migration, and cancer stem cell-like properties by downregulating tumor suppressor genes such as FOXO3, RUNX3, and AKAP13[1][2][3]. Elevated miR-629 expression is associated with more advanced disease, metastasis, and poor prognosis, making it a potential therapeutic target and prognostic biomarker in oncology[1][2][3]. No approved drugs specifically target miR-629, but experimental approaches using antisense oligonucleotides (antagomirs) to inhibit its activity have shown promise in preclinical cancer models[1][2].

Other names

hsa-mir-629MIR629MIRN629mir-629miR-629-5p

RNA interference/antagomir: Direct inhibition of miR-629 to restore expression of targeted tumor suppressor genes (e.g., FOXO3, RUNX3, AKAP13)